Dominick Colangelo Vericel Corp (VCEL) insider trading activity

Dominick Colangelo is President and CEO of Vericel Corp. Currently has a direct ownership of 220,937 shares of VCEL, which is worth approximately $13.2 Million. The most recent transaction as insider was on May 16, 2024, when has been sold 17,500 shares (Common Stock) at a price of $3.02 per share, resulting in proceeds of $52,850. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 221K

0% 3M change

29.97% 12M change

Total Value Held $13.2 Million

Dominick Colangelo Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 16 2024	BUY Exercise of conversion of derivative security	$52,850 $3.02 p/Share	17,500 Added 6.84%	238,252 Common Stock
May 15 2024	SELL Open market or private sale	$869,225 $49.67 p/Share	17,500 Reduced 7.35%	220,752 Common Stock
May 15 2024	BUY Exercise of conversion of derivative security	$52,850 $3.02 p/Share	17,500 Added 6.84%	238,252 Common Stock
Apr 30 2024	BUY Exercise of conversion of derivative security	$354,957 $13.95 p/Share	25,445 Added 10.34%	220,752 Common Stock
Apr 18 2024	SELL Open market or private sale	$780,325 $44.59 p/Share	17,500 Reduced 8.22%	195,307 Common Stock
Apr 18 2024	BUY Exercise of conversion of derivative security	$52,850 $3.02 p/Share	17,500 Added 7.6%	212,807 Common Stock
Apr 17 2024	SELL Open market or private sale	$813,225 $46.47 p/Share	17,500 Reduced 8.22%	195,307 Common Stock
Apr 17 2024	BUY Exercise of conversion of derivative security	$52,850 $3.02 p/Share	17,500 Added 7.6%	212,807 Common Stock
Mar 14 2024	SELL Open market or private sale	$770,350 $44.02 p/Share	17,500 Reduced 8.24%	194,870 Common Stock
Mar 14 2024	BUY Exercise of conversion of derivative security	$52,850 $3.02 p/Share	17,500 Added 7.61%	212,370 Common Stock
Mar 13 2024	SELL Open market or private sale	$781,725 $44.67 p/Share	17,500 Reduced 8.24%	194,870 Common Stock
Mar 13 2024	BUY Exercise of conversion of derivative security	$52,850 $3.02 p/Share	17,500 Added 7.61%	212,370 Common Stock
Feb 20 2024	SELL Payment of exercise price or tax liability	$892,237 $49.5 p/Share	18,025 Reduced 8.47%	194,870 Common Stock
Feb 20 2024	BUY Exercise of conversion of derivative security	-	38,887 Added 16.35%	199,013 Common Stock
Feb 15 2024	SELL Open market or private sale	$854,875 $48.85 p/Share	17,500 Reduced 9.14%	174,008 Common Stock
Feb 15 2024	BUY Exercise of conversion of derivative security	$52,850 $3.02 p/Share	17,500 Added 8.37%	191,508 Common Stock
Feb 14 2024	SELL Open market or private sale	$822,325 $46.99 p/Share	17,500 Reduced 9.14%	174,008 Common Stock
Feb 14 2024	BUY Exercise of conversion of derivative security	$52,850 $3.02 p/Share	17,500 Added 8.37%	191,508 Common Stock
Feb 12 2024	SELL Payment of exercise price or tax liability	$164,879 $47.42 p/Share	3,477 Reduced 1.96%	174,008 Common Stock
Feb 12 2024	BUY Exercise of conversion of derivative security	-	7,500 Added 4.05%	177,485 Common Stock
Jan 18 2024	SELL Open market or private sale	$645,289 $38.58 p/Share	16,726 Reduced 8.96%	169,985 Common Stock
Jan 18 2024	BUY Exercise of conversion of derivative security	$50,512 $3.02 p/Share	16,726 Added 8.22%	186,711 Common Stock
Jan 17 2024	SELL Open market or private sale	$635,086 $37.97 p/Share	16,726 Reduced 8.96%	169,985 Common Stock
Jan 17 2024	BUY Exercise of conversion of derivative security	$50,512 $3.02 p/Share	16,726 Added 8.22%	186,711 Common Stock
Dec 14 2023	SELL Open market or private sale	$445,439 $37.12 p/Share	12,000 Reduced 6.59%	169,985 Common Stock

Also insider at

TRVI

Trevi Therapeutics, Inc. Healthcare